September 23, 2015
A Pennsylvania federal judge nixed claims from consumers and wholesalers Wednesday that GlaxoSmithKline paid off generic rivals to keep cheaper versions of antidepressant Wellbutrin XL off the market, ruling that buyers couldn't show that the settlements that let the patent challenge continue violated antitrust law.
August 05, 2015
A class of indirect purchasers in the pay-for-delay litigation against GlaxoSmithKline PLC and others over the antidepressant Wellbutrin XL appealed its decertification to the Third Circuit last week after a Pennsylvania federal judge said it hadn't shown the class was ascertainable.
February 15, 2013
Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court.
July 23, 2012
Biovail Corp., now part of Valeant Pharmaceuticals International Inc., agreed to pay $37.5 million Monday to settle direct purchasers' claims in antitrust multidistrict litigation alleging it conspired to stifle the market for a generic version of antidepressant Wellbutrin XL.
August 15, 2011
A Pennsylvania federal judge on Monday granted class certification to a group of indirect purchasers of Wellbutrin XL and its generic equivalent in a suit that accuses drugmakers Biovail Corp. and GlaxoSmithKline PLC of lodging baseless patent suits to delay the generic competition for the popular antidepressant.